The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis

Cytokine

Volumn 63, Issue 2, 2013, Pages 81-90

  Audo, Rachel ^a,b   Combe, Bernard ^a,b   Hahne, Michael ^a,b   Morel, Jacques ^a,b  

^a CNRS   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Arthritis; Auto immunity; Fibroblast like synoviocytes (FLSs); Joint destruction; TNF related apoptosis inducing ligand (TRAIL)

Indexed keywords

BORTEZOMIB; CISPLATIN; FAS LIGAND; MONOCLONAL ANTIBODY; PACLITAXEL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

AUTOIMMUNITY; CANCER CELL; CANCER THERAPY; DISEASE CONTROL; DISEASE MODEL; HUMAN; HYPERPLASIA; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL HYPERPLASIA; SYNOVIUM;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; HUMANS; HYPERPLASIA; JOINTS; SYNOVIAL MEMBRANE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

ANIMALIA;

EID: 84878986893     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.04.011     Document Type: Review

References (124)

1. Sweeney S.E., Firestein G.S. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004, 36:372-378.
2. Aidinis V., Plows D., Haralambous S., Armaka M., Papadopoulos P., Kanaki M.Z., et al. Functional analysis of an arthritogenic synovial fibroblast. Arthritis Res Ther 2003, 5:R140-R157.
3. Tolboom T.C., Pieterman E., van der Laan W.H., Toes R.E., Huidekoper A.L., Nelissen R.G., et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002, 61:975-980.
4. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med 2003, 45:7-13.
5. Cha H.S., Ahn K.S., Jeon C.H., Kim J., Song Y.W., Koh E.M. Influence of hypoxia on the expression of matrix metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts. Clin Exp Rheumatol 2003, 21:593-598.
6. Nonomura Y., Kohsaka H., Nagasaka K., Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003, 171:4913-4919.
7. Muller-Ladner U., Kriegsmann J., Franklin B.N., Matsumoto S., Geiler T., Gay R.E., et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996, 149:1607-1615.
8. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2000, 2:356-360.
9. Xue C., Takahashi M., Hasunuma T., Aono H., Yamamoto K., Yoshino S., et al. Characterisation of fibroblast-like cells in pannus lesions of patients with rheumatoid arthritis sharing properties of fibroblasts and chondrocytes. Ann Rheum Dis 1997, 56:262-267.
10. Asahara H., Hasunuma T., Kobata T., Inoue H., Muller-Ladner U., Gay S., et al. In situ expression of protooncogenes and Fas/Fas ligand in rheumatoid arthritis synovium. J Rheumatol 1997, 24:430-435.
11. Pope R.M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002, 2:527-535.
12. Roberts L., McColl G.J. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Int Med J 2004, 34:687-693.
13. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 2004, 64:1267-1283.
14. Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999, 256:449-455.
15. Schneider P., Olson D., Tardivel A., Browning B., Lugovskoy A., Gong D., et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2003, 278:5444-5454.
16. Merino D., Lalaoui N., Morizot A., Solary E., Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007, 11:1299-1314.
17. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006, 26:7046-7055.
18. Kimberley F.C., Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004, 14:359-372.
19. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 2005, 280:40599-40608.
20. Rimondi E., Secchiero P., Quaroni A., Zerbinati C., Capitani S., Zauli G. Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. J Cell Physiol 2006, 206:647-654.
21. O'Flaherty J., Mei Y., Freer M., Weyman C.M. Signaling through the TRAIL receptor DR5/FADD pathway plays a role in the apoptosis associated with skeletal myoblast differentiation. Apoptosis 2006, 11:2103-2113.
22. Yen M.L., Tsai H.F., Wu Y.Y., Hwa H.L., Lee B.H., Hsu P.N. TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells. Mol Immunol 2008, 45:2205-2213.
23. Belyanskaya L.L., Ziogas A., Hopkins-Donaldson S., Kurtz S., Simon H.U., Stahel R., et al. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer 2008, 60:355-365.
24. Kavurma M.M., Schoppet M., Bobryshev Y.V., Khachigian L.M., Bennett M.R. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 2008, 283:7754-7762.
25. Morel J., Audo R., Hahne M., Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005, 280:15709-15718.
26. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003, 107:2250-2256.
27. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004, 61:1965-1974.
28. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22:3842-3852.
29. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
30. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798.
31. Finnberg N., Klein-Szanto A.J., El-Deiry W.S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008, 118:111-123.
32. Cretney E., Shanker A., Yagita H., Smyth M.J., Sayers T.J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006, 84:87-98.
33. Korb A., Pavenstadt H., Pap T. Cell death in rheumatoid arthritis. Apoptosis 2009, 14:447-454.
34. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000, 191:1095-1104.
35. Jin C.H., Chae S.Y., Kim T.H., Yang H.K., Lee E.Y., Song Y.W., et al. Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis. J Pharmacol Exp Ther 2010, 332:858-865.
36. Martinez-Lostao L., Garcia-Alvarez F., Basanez G., Alegre-Aguaron E., Desportes P., Larrad L., et al. Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum 2010, 62:2272-2282.
37. Audo R., Calmon-Hamaty F., Baeten D., Bruyer A., Combe B., Hahne M., et al. Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 2011, 63:904-913.
38. Xiao H., Wang S., Miao R., Kan W. TRAIL is associated with impaired regulation of CD4+CD25-T cells by regulatory T cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:1112-1119.
39. Pettersen I., Figenschau Y., Olsen E., Bakkelund W., Smedsrod B., Sveinbjornsson B. Tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in human articular chondrocytes in vitro. Biochem Biophys Res Commun 2002, 296:671-676.
40. Vitovski S., Phillips J.S., Sayers J., Croucher P.I. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007, 282:31601-31609.
41. Lamhamedi-Cherradi S.E., Zheng S.J., Maguschak K.A., Peschon J., Chen Y.H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 2003, 4:255-260.
42. Liu Z., Xu X., Hsu H.C., Tousson A., Yang P.A., Wu Q., et al. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 2003, 112:1332-1341.
43. Yao Q., Wang S., Gambotto A., Glorioso J.C., Evans C.H., Robbins P.D., et al. Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther 2003, 10:1055-1060.
44. Salehi E., Vodjgani M., Massoud A., Keyhani A., Rajab A., Shafaghi B., et al. Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients. Iran J Immunol 2007, 4:197-205.
45. Lub-de Hooge M.N., de Vries E.G., de Jong S., Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64:854-858.
46. Hofbauer L.C., Schoppet M., Christ M., Teichmann J., Lange U. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxford) 2006, 45:1218-1222.
47. Kaplan M.J., Lewis E.E., Shelden E.A., Somers E., Pavlic R., McCune W.J., et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002, 169:6020-6029.
48. Corazza N., Brumatti G., Schaer C., Cima I., Wasem C., Brunner T. TRAIL and immunity: more than a license to kill tumor cells. Cell Death Differ 2004, 11(Suppl. 2):S122-S125.
49. Castellino G., Corallini F., Trotta F., Secchiero P. Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?. Ann Rheum Dis 2008, 67:1196-1197.
50. Jungel A., Baresova V., Ospelt C., Simmen B.R., Michel B.A., Gay R.E., et al. Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 2006, 65:910-912.
51. Dharmapatni A.A., Smith M.D., Findlay D.M., Holding C.A., Evdokiou A., Ahern M.J., et al. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 2009, 11:R13.
52. Morales-Lara M.J., Canete J.D., Torres-Moreno D., Hernandez M.V., Pedrero F., Celis R., et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012.
53. Kayagaki N., Yamaguchi N., Abe M., Hirose S., Shirai T., Okumura K., et al. Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell Immunol 2002, 219:82-91.
54. Ursini-Siegel J., Zhang W., Altmeyer A., Hatada E.N., Do R.K., Yagita H., et al. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol 2002, 169:5505-5513.
55. Hilliard B., Wilmen A., Seidel C., Liu T.S., Goke R., Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001, 166:1314-1319.
56. Lunemann J.D., Waiczies S., Ehrlich S., Wendling U., Seeger B., Kamradt T., et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002, 168:4881-4888.
57. Bosque A., Pardo J., Martinez-Lorenzo M.J., Iturralde M., Marzo I., Pineiro A., et al. Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c-FLIP, Bim, or Bcl-x isoform expression. J Leukoc Biol 2005, 77:568-578.
58. Bosque A., Pardo J., Martinez-Lorenzo M.J., Lasierra P., Larrad L., Marzo I., et al. Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL. Eur J Immunol 2005, 35:1812-1821.
59. Martinez-Lorenzo M.J., Anel A., Saez-Gutierrez B., Royo-Canas M., Bosque A., Alava M.A., et al. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol 2007, 122:28-40.
60. Kraan M.C., Haringman J.J., Weedon H., Barg E.C., Smith M.D., Ahern M.J., et al. T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004, 63:483-488.
61. Kang Y.M., Zhang X., Wagner U.G., Yang H., Beckenbaugh R.D., Kurtin P.J., et al. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 2002, 195:1325-1336.
62. Wang S.H., Chen G.H., Fan Y., Van Antwerp M., Baker J.R. Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4+CD25+ regulatory T cells. Endocrinology 2009, 150:2000-2007.
63. Ikeda T., Hirata S., Fukushima S., Matsunaga Y., Ito T., Uchino M., et al. Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J Immunol 2010, 185:5259-5267.
64. Martinez-Lorenzo M.J., Anel A., Gamen S., Monlen I., Lasierra P., Larrad L., et al. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 1999, 163:1274-1281.
65. Martinez-Lorenzo M.J., Alava M.A., Gamen S., Kim K.J., Chuntharapai A., Pineiro A., et al. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998, 28:2714-2725.
66. Jeremias I., Herr I., Boehler T., Debatin K.M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998, 28:143-152.
67. Sun M., Fink P.J. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol 2007, 179:4307-4312.
68. Chou A.H., Tsai H.F., Lin L.L., Hsieh S.L., Hsu P.I., Hsu P.N. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 2001, 167:1347-1352.
69. Tsai H.F., Lai J.J., Chou A.H., Wang T.F., Wu C.S., Hsu P.N. Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus. Arthritis Rheum 2004, 50:629-639.
70. Simon A.K., Williams O., Mongkolsapaya J., Jin B., Xu X.N., Walczak H., et al. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci USA 2001, 98:5158-5163.
71. Cretney E., Uldrich A.P., Berzins S.P., Strasser A., Godfrey D.I., Smyth M.J. Normal thymocyte negative selection in TRAIL-deficient mice. J Exp Med 2003, 198:491-496.
72. Cretney E., Uldrich A.P., McNab F.W., Godfrey D.I., Smyth M.J. No requirement for TRAIL in intrathymic negative selection. Int Immunol 2008, 20:267-276.
73. Diehl G.E., Yue H.H., Hsieh K., Kuang A.A., Ho M., Morici L.A., et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004, 21:877-889.
74. Walsh C.M., Wen B.G., Chinnaiyan A.M., O'Rourke K., Dixit V.M., Hedrick S.M. A role for FADD in T cell activation and development. Immunity 1998, 8:439-449.
75. Newton K., Harris A.W., Bath M.L., Smith K.G., Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. Embo J 1998, 17:706-718.
76. Kinne R.W., Brauer R., Stuhlmuller B., Palombo-Kinne E., Burmester G.R. Macrophages in rheumatoid arthritis. Arthritis Res 2000, 2:189-202.
77. Schett G., Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012, 8:656-664.
78. Perlman H., Nguyen N., Liu H., Eslick J., Esser S., Walsh K., et al. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3. Arthritis Rheum 2003, 48:3096-3101.
79. Li J., Hsu H.C., Yang P., Wu Q., Li H., Edgington L.E., et al. Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model. Arthritis Rheum 2012, 64:1098-1109.
80. Cascao R., Rosario H.S., Souto-Carneiro M.M., Fonseca J.E. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010, 9:531-535.
81. Renshaw S.A., Parmar J.S., Singleton V., Rowe S.J., Dockrell D.H., Dower S.K., et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003, 170:1027-1033.
82. Lum J.J., Bren G., McClure R., Badley A.D. Elimination of senescent neutrophils by TNF-related apoptosis-inducing [corrected] ligand. J Immunol 2005, 175:1232-1238.
83. McGrath E.E., Marriott H.M., Lawrie A., Francis S.E., Sabroe I., Renshaw S.A., et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol 2011, 90:855-865.
84. Miyashita T., Kawakami A., Nakashima T., Yamasaki S., Tamai M., Tanaka F., et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 2004, 137:430-436.
85. Ichikawa K., Liu W., Fleck M., Zhang H., Zhao L., Ohtsuka T., et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003, 171:1061-1069.
86. Miranda-Carus M.E., Balsa A., Benito-Miguel M., De Ayala C.P., Martin-Mola E. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 2004, 50:2786-2793.
87. Audo R., Combe B., Coulet B., Morel J., Hahne M. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death Differ 2009, 16:1227-1237.
88. Miyashita T., Kawakami A., Tamai M., Izumi Y., Mingguo H., Tanaka F., et al. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem Biophys Res Commun 2003, 312:397-404.
89. Audo R., Deschamps V., Hahne M., Combe B., Morel J. Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2007, 9:R128.
90. Terzioglu E., Bisgin A., Sanlioglu A.D., Ulker M., Yazisiz V., Tuzuner S., et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:783-789.
91. Yao Q., Seol D.W., Mi Z., Robbins P.D. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res Ther 2006, 8:R16.
92. Fujikawa K., Kawakami A., Tanaka F., Iwamoto N., Tamai M., Eguchi K. Calcium/calmodulin-dependent protein kinase II (CaMKII) regulates tumour necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells (FLS) by phosphorylation of Akt. Clin Exp Rheumatol 2009, 27:952-957.
93. Sun Q.W., Jiang S.M., Yang K., Zheng J.M., Zhang L., Xu W.D. Apigenin enhances the cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand in human rheumatoid arthritis fibroblast-like synoviocytes. Mol Biol Rep 2012, 39:5529-5535.
94. in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 2012, 64:1771-1779.
95. Park Y.W., Ji J.D., Lee J.S., Ryang D.W., Yoo D.H. Actinomycin D renders cultured synovial fibroblasts susceptible to tumour necrosis factor related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Scand J Rheumatol 2003, 32:356-363.
96. Otero M., Goldring M.B. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res Ther 2007, 9:220.
97. Lee S.W., Lee H.J., Chung W.T., Choi S.M., Rhyu S.H., Kim D.K., et al. TRAIL induces apoptosis of chondrocytes and influences the pathogenesis of experimentally induced rat osteoarthritis. Arthritis Rheum 2004, 50:534-542.
98. Roux S., Lambert-Comeau P., Saint-Pierre C., Lepine M., Sawan B., Parent J.L. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun 2005, 333:42-50.
99. Brunetti G., Oranger A., Mori G., Tamma R., Di Benedetto A., Pignataro P., et al. TRAIL is involved in human osteoclast apoptosis. Ann NY Acad Sci 2007, 1116:316-322.
100. Colucci S., Brunetti G., Cantatore F.P., Oranger A., Mori G., Pignataro P., et al. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 2007, 12:1623-1632.
101. Chamoux E., Houde N., L'Eriger K., Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol 2008, 216:536-542.
102. Zauli G., Rimondi E., Stea S., Baruffaldi F., Stebel M., Zerbinati C., et al. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 2008, 214:117-125.
103. Zauli G., Rimondi E., Nicolin V., Melloni E., Celeghini C., Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 2004, 104:2044-2050.
104. Labrinidis A., Liapis V., Thai le M., Atkins G.J., Vincent C., Hay S., et al. Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?. Blood 2008, 111:5411-5412. autor reply 3.
105. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
106. Brunetti G., Oranger A., Mori G., Sardone F., Pignataro P., Coricciati M., et al. TRAIL effect on osteoclast formation in physiological and pathological conditions. Front Biosci (Elite Ed.) 2011, 3:1154-1161.
107. Narducci P., Bareggi R., Nicolin V. Interaction of human recombinant tumor necrosis factor-related apoptosis-inducing ligand and osteoprotegerin could contribute to enhancement of the erosive processes induced by human synovial cells. J Rheumatol 2009, 36:1837-1839.
108. Atkins G.J., Bouralexis S., Evdokiou A., Hay S., Labrinidis A., Zannettino A.C., et al. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 2002, 31:448-456.
109. Mori G., Brunetti G., Colucci S., Ciccolella F., Coricciati M., Pignataro P., et al. Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: role of TRAIL. J Biol Regul Homeost Agents 2007, 21:105-114.
110. Tinhofer I., Biedermann R., Krismer M., Crazzolara R., Greil R. A role of TRAIL in killing osteoblasts by myeloma cells. Faseb J 2006, 20:759-761.
111. Fu J., Wang P., Zhang X., Ju S., Li J., Li B., et al. Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis. Arch Med Sci 2010, 6:496-504.
112. Young A.B., Cooley I.D., Chauhan V.S., Marriott I. Causative agents of osteomyelitis induce death domain-containing TNF-related apoptosis-inducing ligand receptor expression on osteoblasts. Bone 2011, 48:857-863.
113. Mahmood Z., Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res 2010, 316:887-899.
114. Hellwig C.T., Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012, 11:3-13.
115. Takeda K., Stagg J., Yagita H., Okumura K., Smyth M.J. Targeting death-inducing receptors in cancer therapy. Oncogene 2007, 26:3745-3757.
116. Stadel D., Mohr A., Ref C., MacFarlane M., Zhou S., Humphreys R., et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010, 16:5734-5749.
117. Dolcet X., Llobet D., Pallares J., Rue M., Comella J.X., Matias-Guiu X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005, 85:885-894.
118. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002, 8:274-281.
119. Secchiero P., Corallini F., Castellino G., Bortoluzzi A., Caruso L., Bugatti S., et al. Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying antirheumatic drugs. J Rheumatol 2010, 37:1461-1466.
120. Shipman C.M., Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003, 63:912-916.
121. Kawano Y., Ueno S., Abe M., Kikukawa Y., Yuki H., Iyama K., et al. TRAIL produced from multiple myeloma cells is associated with osteolytic markers. Oncol Rep 2012, 27:39-44.
122. de Kluyver R.L., Sayers T.J. Breast cancer bone metastases: combination therapy targeting cancer cells and the tumor microenvironment. Cancer Biol Ther 2010, 9:551-553.
123. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008, 26:3621-3630.
124. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005, 280:2205-2212.